Quick Answer
Elicio Therapeutics, Inc. reported Total Revenue of $2.30 million for fiscal year 2022.
Elicio Therapeutics, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | — | — | — | $2.30M -91.9% |
$28.31M +883.1% |
$2.88M |
| Net Income | -$39.57M +23.8% |
-$51.90M -47.5% |
-$35.20M -24.8% |
-$28.21M +48.3% |
-$54.57M +31.9% |
-$80.11M |
| Diluted EPS | -$2.58 +39.3% |
-$4.25 +38.9% |
-$6.96 +92.2% |
-$89.27 -4525.4% |
-$1.93 +64.5% |
-$5.43 |
| Total Assets | $25.86M -8.2% |
$28.18M +3.8% |
$27.15M +19.8% |
$22.66M -76.5% |
$96.51M +103.8% |
$47.35M |
| Cash and Equivalents | $18.56M +5.4% |
$17.62M +36.6% |
$12.89M +109.5% |
$6.16M -93.1% |
$88.76M +156.5% |
$34.61M |
| Long-Term Debt | $9.41M -53.0% |
$20.03M | — | — | $0.00 -100.0% |
$635.0K |
| Stockholders Equity | $1.64M +114.5% |
-$11.31M -199.5% |
$11.37M +111.1% |
-$102.14M -37.0% |
-$74.54M +17.6% |
-$90.45M -386.7% |
| R&D Expense | $24.90M -26.0% |
$33.66M +41.1% |
$23.85M +31.7% |
$18.10M -62.8% |
$48.70M +24.9% |
$38.98M |
| Operating Income | -$37.71M +16.2% |
-$44.99M -25.9% |
-$35.74M -50.6% |
-$23.73M +39.6% |
-$39.31M +28.9% |
-$55.27M |
| Shares Outstanding | 17.80M +61.4% |
11.03M +31.5% |
8.39M +2518.6% |
320,281 -98.9% |
29.96M +95.6% |
15.32M |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | March 31, 2023 | $0.00 | -100.0% | — |
| Net Income | September 30, 2025 | -$10.08M | +46.5% | +4.5% |
| Diluted EPS | September 30, 2025 | -$0.60 | +56.8% | +9.1% |
| Total Assets | September 30, 2025 | $28.28M | -26.3% | -4.2% |
| Cash and Equivalents | September 30, 2025 | $20.61M | -20.8% | -6.7% |
| Long-Term Debt | September 30, 2025 | $9.72M | — | +4.1% |
| Stockholders Equity | September 30, 2025 | $3.82M | +120.1% | +108.1% |
| R&D Expense | September 30, 2025 | $5.04M | -30.1% | -28.1% |
| Operating Income | September 30, 2025 | -$8.04M | +22.2% | +20.3% |
| Shares Outstanding | September 30, 2025 | 17.26M | +60.0% | +6.1% |
- Elicio Therapeutics, Inc. reported Total Revenue of $2.30 million for fiscal year 2022.
- Elicio Therapeutics, Inc. showed a decrease of -91.9% in Total Revenue compared to the prior fiscal year.
- Elicio Therapeutics, Inc. reported Net Income of -$39.57 million for fiscal year 2025.
- Elicio Therapeutics, Inc. showed an increase of +23.8% in Net Income compared to the prior fiscal year.
- Elicio Therapeutics, Inc. reported Diluted EPS of $2.58 per share (loss) for fiscal year 2025.
- Elicio Therapeutics, Inc. showed an increase of +39.3% in Diluted EPS compared to the prior fiscal year.
- Elicio Therapeutics, Inc. reported Total Assets of $25.86 million for fiscal year 2025.
- Elicio Therapeutics, Inc. showed a decrease of -8.2% in Total Assets compared to the prior fiscal year.
- Elicio Therapeutics, Inc. reported Cash and Equivalents of $18.56 million for fiscal year 2025.
- Elicio Therapeutics, Inc. showed an increase of +5.4% in Cash and Equivalents compared to the prior fiscal year.
- Elicio Therapeutics, Inc. reported Long-Term Debt of $9.41 million for fiscal year 2025.
- Elicio Therapeutics, Inc. showed a decrease of -53.0% in Long-Term Debt compared to the prior fiscal year.
- Elicio Therapeutics, Inc. reported Stockholders Equity of $1.64 million for fiscal year 2025.
- Elicio Therapeutics, Inc. showed an increase of +114.5% in Stockholders Equity compared to the prior fiscal year.
- Elicio Therapeutics, Inc. reported R&D Expense of $24.90 million for fiscal year 2025.
- Elicio Therapeutics, Inc. showed a decrease of -26.0% in R&D Expense compared to the prior fiscal year.
- Elicio Therapeutics, Inc. reported Operating Income of -$37.71 million for fiscal year 2025.
- Elicio Therapeutics, Inc. showed an increase of +16.2% in Operating Income compared to the prior fiscal year.
- Elicio Therapeutics, Inc. reported Shares Outstanding of 17.80 million shares for fiscal year 2025.
- Elicio Therapeutics, Inc. showed an increase of +61.4% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: